Literature DB >> 17083040

Long-term variations in human T lymphotropic virus (HTLV)-I and HTLV-II proviral loads and association with clinical data.

Nicholas Kwaan1, Tzong-Hae Lee, Daniel M Chafets, Catharie Nass, Bruce Newman, James Smith, George Garratty, Edward L Murphy.   

Abstract

BACKGROUND: The human T lymphotropic virus (HTLV)-I or -II proviral load (VL) may be linked to viral pathogenesis, but prospective data on VL and disease outcomes are lacking.
METHODS: Using data from a prospective cohort study of HTLV disease outcomes, we examined baseline VLs with real-time quantitative polymerase chain reaction in 122 HTLV-I- and 319 HTLV-II-infected subjects and serial VLs over the course of 6 visits in a subset of 30 HTLV-I- and 30 HTLV-II-infected subjects. Cox and logistic-regression models were used to test baseline associations, and repeated-measures analysis was used to study variations in VL over time.
RESULTS: Over the course of a median of 10.4 years, HTLV-I VLs decreased slightly (slope, -0.017 log(10) copies/10(6) peripheral blood mononuclear cells [PBMCs]/year; P=.042) and HTLV-II VLs did not change (slope, -0.019 log(10) copies/10(6) PBMCs/year; P=.165). Changes in VL over time were associated positively with alcohol use (P=.07) and negatively with black race (P=.03) for HTLV-I and positively with smoking (P=.08) for HTLV-II. In the larger group, there was no association between baseline VL and disease outcomes. In the smaller group with serial VL data, there was an association between increasing VL and bladder or kidney infections for both HTLV-I (P=.005) and HTLV-II (P=.022).
CONCLUSIONS: HTLV VLs are stable over time, but alcohol and tobacco intake may affect the progression of VLs. The association between increasing VLs and bladder/kidney infection may be explained by early HTLV-related neuropathologic progression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17083040     DOI: 10.1086/508899

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  21 in total

1.  HTLV-2 APH-2 expression is correlated with proviral load but APH-2 does not promote lymphocytosis.

Authors:  Estelle Douceron; Zhanna Kaidarova; Paola Miyazato; Masao Matsuoka; Edward L Murphy; Renaud Mahieux
Journal:  J Infect Dis       Date:  2011-11-07       Impact factor: 5.226

2.  Long-term follow-up of HTLV-1 proviral load in asymptomatic carriers and in incident cases of HAM/TSP: what is its relevance as a prognostic marker for neurologic disease?

Authors:  Marina Lobato Martins; Jacqueline Cronemberger Guimarães; João Gabriel Ribas; Luiz Cláudio Ferreira Romanelli; Anna Bárbara de Freitas Carneiro-Proietti
Journal:  J Neurovirol       Date:  2016-09-27       Impact factor: 2.643

Review 3.  Molecular biology of human T cell leukemia virus.

Authors:  Lee Ratner
Journal:  Semin Diagn Pathol       Date:  2019-04-16       Impact factor: 3.464

4.  The National Heart, Lung, and Blood Institute retrovirus epidemiology donor studies (Retrovirus Epidemiology Donor Study and Retrovirus Epidemiology Donor Study-II): twenty years of research to advance blood product safety and availability.

Authors:  Steven Kleinman; Melissa R King; Michael P Busch; Edward L Murphy; Simone A Glynn
Journal:  Transfus Med Rev       Date:  2012-05-24

5.  Subacute progression of human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis.

Authors:  Marco A Lima; Ramza C Harab; Doris Schor; Maria J Andrada-Serpa; Abelardo Q C Araújo
Journal:  J Neurovirol       Date:  2007-10       Impact factor: 2.643

6.  Preexisting infection with human T-cell lymphotropic virus type 2 neither exacerbates nor attenuates simian immunodeficiency virus SIVmac251 infection in macaques.

Authors:  Shari N Gordon; Anna R Weissman; Valentina Cecchinato; Claudio Fenizia; Zhong-Min Ma; Tzong-Hae Lee; Lorenzo Zaffiri; Vibeke Andresen; Robyn Washington Parks; Kathryn S Jones; Jean Michel Heraud; Maria Grazia Ferrari; Hye Kyung Chung; David Venzon; Renaud Mahieux; Edward L Murphy; Steven Jacobson; Christopher J Miller; Francis W Ruscetti; Genoveffa Franchini
Journal:  J Virol       Date:  2010-01-13       Impact factor: 5.103

7.  IFN-gamma production in response to Tax 161-233, and frequency of CD4+ Foxp3+ and Lin HLA-DRhigh CD123+ cells, discriminate HAM/TSP patients from asymptomatic HTLV-1-carriers in a Peruvian population.

Authors:  Ivan Best; Giovanni López; Kristien Verdonck; Elsa González; Martín Tipismana; Eduardo Gotuzzo; Guido Vanham; Daniel Clark
Journal:  Immunology       Date:  2009-02-17       Impact factor: 7.397

8.  Long-term increases in lymphocytes and platelets in human T-lymphotropic virus type II infection.

Authors:  Melissa T Bartman; Zhanna Kaidarova; Dale Hirschkorn; Ronald A Sacher; Joy Fridey; George Garratty; Joan Gibble; James W Smith; Bruce Newman; Anthony E Yeo; Edward L Murphy
Journal:  Blood       Date:  2008-08-28       Impact factor: 22.113

9.  Prognosis Markers for Monitoring HTLV-1 Neurologic Disease.

Authors:  Gabriela Prates; Tatiane Assone; Marcelo Corral; Maíra P M Baldassin; Tatiane Mitiko; Flávia C Silva Sales; Michel E Haziot; Jerusa Smid; Luiz A M Fonseca; Fernanda de Toledo Gonçalves; Augusto C Penalva de Oliveira; Jorge Casseb
Journal:  Neurol Clin Pract       Date:  2021-04

10.  Comparison of the Genetic Organization, Expression Strategies and Oncogenic Potential of HTLV-1 and HTLV-2.

Authors:  Francesca Rende; Ilaria Cavallari; Maria Grazia Romanelli; Erica Diani; Umberto Bertazzoni; Vincenzo Ciminale
Journal:  Leuk Res Treatment       Date:  2011-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.